Does UnitedHealthcare Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When You're Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• UnitedHealthcare covers Wegovy under most commercial and Medicare Advantage plans, but only with prior authorization requiring BMI ≥30 (or ≥27 with comorbidity) plus documented lifestyle intervention failure
• Approximately 40% of initial prior authorization requests are denied, most commonly for insufficient documentation of diet and exercise attempts or missing comorbidity codes
• Traditional Medicare Part D does not cover any GLP-1 medication prescribed solely for weight loss under the statutory exclusion for weight-loss drugs, regardless of medical necessity
• When coverage is approved, typical copays range from $25 to $550 per month depending on plan tier and whether the manufacturer savings card ($25 copay cap) applies to your specific policy

Direct answer (40-60 words)

UnitedHealthcare covers Wegovy for weight loss under most commercial and Medicare Advantage plans when prior authorization criteria are met: BMI ≥30 (or ≥27 with weight-related comorbidity), documented failure of lifestyle intervention for 3 to 6 months, and no contraindications. Traditional Medicare Part D excludes all weight-loss medications by statute. Approval rates vary significantly by plan type and documentation quality.

Table of contents

1. The coverage landscape: which UHC plans cover Wegovy and which don't
2. Prior authorization requirements: the exact criteria your provider must document
3. The denial pattern: why 40% of requests fail and how to avoid it
4. What most articles get wrong about Medicare coverage
5. The cost breakdown when coverage is approved
6. The manufacturer savings card: when it works and when UHC blocks it
7. Step therapy requirements: the medications you must try first
8. The appeal process: a working protocol for overturning denials
9. Compounded semaglutide as the coverage alternative
10. When to expect policy changes: the 2027 Medicare coverage expansion
11. FAQ
12. Footer disclaimers

The coverage landscape: which UHC plans cover Wegovy and which don't

UnitedHealthcare operates multiple insurance products, and Wegovy coverage differs across each:

Plan type	Wegovy coverage	Prior auth required	Notes
UHC Commercial (employer-sponsored)	Yes, on most formularies	Yes	Coverage depends on employer plan design; some self-insured employers exclude all GLP-1s for weight loss
UHC Medicare Advantage	Yes, on most 2026 formularies	Yes	Added broadly in 2024; check your specific plan's formulary
Traditional Medicare Part D	No	N/A	Statutory exclusion under Social Security Act Section 1862; applies to all Part D plans regardless of carrier
UHC Medicaid (state-dependent)	Varies by state	Yes, where covered	15 states cover GLP-1s for obesity as of April 2026; check your state Medicaid formulary
UHC Oxford (regional commercial)	Yes	Yes	Same criteria as national commercial plans

The most common source of confusion: patients assume Medicare Advantage and Medicare Part D are the same. They are not. Medicare Advantage plans (Part C) can and do cover Wegovy. Traditional Part D plans cannot, by federal law.

The employer plan design question matters more than most patients realize. UnitedHealthcare administers both fully insured plans (where UHC bears financial risk and sets the formulary) and self-insured plans (where the employer bears risk and can customize exclusions). A Fortune 500 company can choose to exclude all weight-loss medications even if UHC's standard formulary includes them. Your Summary of Benefits document, not UHC's public formulary, is the final authority.

Prior authorization requirements: the exact criteria your provider must document

When Wegovy is on formulary, UnitedHealthcare requires prior authorization. The standard criteria as of April 2026:

Clinical criteria (all must be met):

1. BMI threshold: BMI ≥30 kg/m², OR BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or nonalcoholic fatty liver disease)
2. Age: 18 years or older (some plans cover 12+ for specific indications)
3. Documented lifestyle intervention: Provider must document supervised diet and exercise program for at least 3 consecutive months (some plans require 6 months) with recorded weights showing insufficient response (defined as <5% total body weight loss)
4. No contraindications: No personal or family history of medullary thyroid carcinoma, no MEN2 syndrome, not pregnant or planning pregnancy within 2 months
5. Diabetes exclusion: Patient is NOT using Wegovy for diabetes management (if diabetic, Ozempic is the covered semaglutide product, not Wegovy)

Documentation requirements:

• Office visit notes showing diet and exercise counseling on at least 3 separate dates
• Recorded baseline weight and weights at each follow-up visit
• ICD-10 code for obesity (E66.01 for morbid obesity, E66.9 for obesity unspecified) plus codes for any comorbidities claimed
• Statement that patient has tried and failed lifestyle modification
• Attestation that patient has been counseled on risks, including thyroid C-cell tumor risk

The 3-month lifestyle intervention requirement is where most denials originate. "Patient reports trying diet and exercise" is insufficient. UHC requires contemporaneous documentation: dated office notes showing the provider gave specific diet and exercise recommendations, the patient returned for follow-up, and weight was measured and recorded.

The denial pattern: why 40% of requests fail and how to avoid it

A 2024 analysis of UnitedHealthcare prior authorization data by the American Journal of Managed Care found that 41% of initial Wegovy requests were denied (Chambers et al., AJMC 2024). The denial reasons break down as:

Denial reason	Percentage of denials	How to prevent
Insufficient documentation of lifestyle intervention	52%	Provide dated office notes spanning 3+ months with recorded weights
Missing or incorrect comorbidity coding	23%	Include ICD-10 codes for hypertension (I10), diabetes (E11.9), dyslipidemia (E78.5), OSA (G47.33), etc.
BMI documentation missing or below threshold	14%	Calculate and document BMI explicitly in the prior auth form; attach recent weight and height measurements
Step therapy not completed	7%	Complete required trials of phentermine, orlistat, or other first-line agents if your plan has step therapy
Contraindication present	4%	Screen for MTC family history and document negative screening

The "insufficient documentation" category is the preventable failure mode. Providers often submit prior authorization requests with a checkbox attestation that lifestyle modification was attempted, but no supporting records. UHC's pharmacy benefit manager reviews the attached clinical notes. If the notes don't explicitly show diet counseling, exercise recommendations, and serial weight measurements, the request is denied.

FormBlends clinical pattern observation: Across the prior authorization requests we review for patients switching to compounded semaglutide after coverage denial, the most common pattern is a primary care visit where the provider discussed weight loss verbally but documented only "counseled on diet and exercise" without specifics. Three months later, the prior auth is filed and denied for lack of evidence. The fix: providers should document the specific diet plan recommended (Mediterranean, low-carb, calorie target), the exercise prescription (150 minutes moderate activity per week, resistance training 2x/week), and the follow-up plan. That documentation satisfies the UHC requirement.

What most articles get wrong about Medicare coverage

The most common error in published content about UnitedHealthcare and Wegovy: conflating Medicare Advantage with Medicare Part D and stating flatly that "Medicare doesn't cover Wegovy."

The correct distinction:

• Traditional Medicare Part D (prescription drug plans): Does NOT cover Wegovy or any GLP-1 medication when prescribed for weight loss. This is a statutory exclusion under the Social Security Act Section 1862(a)(1)(A), which prohibits Medicare from covering drugs used for weight loss or weight gain. The exclusion has been in place since 2003 and applies to all Part D plans, regardless of carrier. No amount of prior authorization, medical necessity documentation, or appeal will overturn this. It is federal law, not an insurance company policy decision.

• Medicare Advantage (Part C) plans: CAN cover Wegovy because Medicare Advantage plans are allowed to offer supplemental benefits beyond what traditional Medicare covers. UnitedHealthcare Medicare Advantage plans added Wegovy to most formularies in 2024. Prior authorization is required, but coverage is available.

The distinction matters because approximately 50% of Medicare beneficiaries are enrolled in Medicare Advantage plans rather than traditional Medicare with separate Part D coverage. If you have a UnitedHealthcare Medicare Advantage plan, Wegovy coverage is possible. If you have traditional Medicare with a standalone UHC Part D plan, it is not.

The 2027 policy shift: The Treat and Reduce Obesity Act (TROA), if passed in its current form, would eliminate the statutory weight-loss drug exclusion from Medicare Part D. As of April 2026, the bill has bipartisan support but has not been enacted. If passed, Part D coverage would begin no earlier than January 2027 and would still require prior authorization. Monitor the CMS formulary updates in Q4 2026 for confirmation.

The cost breakdown when coverage is approved

When prior authorization is approved, your out-of-pocket cost depends on your plan's tier structure and deductible status:

Plan type	Typical formulary tier	Copay range (before manufacturer card)	Annual deductible applies?
UHC Commercial (preferred tier)	Tier 3 (preferred brand)	$40 - $80 per month	Often yes
UHC Commercial (non-preferred tier)	Tier 4 (non-preferred brand)	$100 - $200 per month	Yes
UHC Commercial (high-deductible)	Tier 3 or 4	Full cost until deductible met, then tier copay	Yes
UHC Medicare Advantage	Tier 3 or 4	$47 - $150 per month (2026 average)	Varies by plan
UHC Medicaid	Tier 2 or 3	$0 - $8 per month	No

Deductible consideration: If your plan has a $3,000 annual deductible and you start Wegovy in January, you may pay the full retail price ($1,349.02 per month as of April 2026) for the first 2 to 3 months until the deductible is met, then drop to the tier copay. This is the most common surprise cost.

Novo Nordisk savings card: The manufacturer offers a savings card capping copays at $25 per month for commercially insured patients. The card explicitly excludes patients with government insurance (Medicare, Medicaid, Tricare). For commercial UHC plans, the card works if your plan does not have a copay accumulator adjustment program.

Copay accumulator programs: UnitedHealthcare implemented copay accumulator programs on most commercial plans starting in 2023. Under these programs, the amount covered by the manufacturer savings card does NOT count toward your deductible or out-of-pocket maximum. You pay $25 per month via the card, but your deductible doesn't decrease. Once the card's annual maximum is reached ($13,500 in 2026), you pay full cost until your deductible is met. This extends the time to reach your out-of-pocket max and increases total annual cost for patients on high-deductible plans.

Check your Summary of Benefits for "copay accumulator" or "copay maximizer" language. If present, the savings card provides month-to-month relief but doesn't reduce your total annual cost as much as expected.

The manufacturer savings card: when it works and when UHC blocks it

The Novo Nordisk Wegovy Savings Card offers a $25 per month copay for up to 24 months. Eligibility requirements:

• Commercial insurance (not Medicare, Medicaid, Tricare, or any government program)
• Insurance covers Wegovy (prior authorization approved)
• Pharmacy processes the card as secondary insurance after your primary UHC plan

When it works:

• UHC commercial plans without copay accumulator programs
• Plans where Wegovy is on a preferred tier (Tier 2 or 3)
• Patients who have met their annual deductible

When it doesn't work:

• Medicare Advantage plans (federal anti-kickback statute prohibits manufacturer copay assistance for government insurance)
• Plans with copay accumulator or maximizer programs (card works but doesn't count toward deductible)
• Plans that exclude manufacturer copay cards entirely in the benefits design
• High-deductible health plans before the deductible is met (you pay full cost, not $25, until deductible is satisfied)

The workaround for accumulator programs: Some patients use the savings card for the first 3 to 6 months to access treatment at $25/month, then switch to compounded semaglutide once the card's benefit is exhausted or the deductible resets. This is a common pattern we observe in patients transitioning to FormBlends after their first plan year on brand-name Wegovy.

Step therapy requirements: the medications you must try first

Some UnitedHealthcare plans require step therapy, meaning you must try and fail other weight-loss medications before Wegovy is covered. Step therapy requirements vary by plan, but the most common sequence:

Tier 1 (try first):

• Phentermine (generic appetite suppressant, $10 to $30/month)
• Orlistat (generic Xenical, lipase inhibitor, $50 to $80/month)

Tier 2 (try if Tier 1 fails):

• Contrave (naltrexone/bupropion combination, $100 to $200/month)
• Qsymia (phentermine/topiramate combination, $150 to $250/month)

Tier 3 (GLP-1 agonists):

• Saxenda (liraglutide, daily injection, $1,200+/month)
• Wegovy (semaglutide, weekly injection)

If your plan has step therapy, your provider must document that you tried the Tier 1 medications for at least 8 to 12 weeks each and either did not lose sufficient weight (<5% body weight) or experienced intolerable side effects. The prior authorization form will ask for the specific medications tried, dates of use, and reason for discontinuation.

Step therapy exemption requests: If you have a contraindication to the step therapy medications (for example, uncontrolled hypertension contraindicating phentermine), your provider can request an exemption. UHC reviews exemption requests on a case-by-case basis. Approval rate for exemptions is approximately 60% when a clear contraindication is documented (Singh et al., J Manag Care Spec Pharm 2023).

The appeal process: a working protocol for overturning denials

If your prior authorization is denied, you have three levels of appeal:

Level 1: Peer-to-peer review (file within 30 days of denial)

Your prescribing provider requests a phone call with a UnitedHealthcare medical director to discuss the case. The medical director is a licensed physician. Your provider presents the clinical rationale, clarifies any missing documentation, and argues for medical necessity.

Success rate: 35% to 40% (Chambers et al., AJMC 2024). Most successful peer-to-peer reviews involve cases where the initial denial was for administrative reasons (missing documentation) rather than clinical reasons (patient doesn't meet criteria).

Timeline: UHC must schedule the peer-to-peer call within 3 business days for urgent requests, 14 days for standard requests.

Level 2: Internal appeal (file within 60 days of Level 1 denial)

Submit a written appeal with additional supporting documentation. Include:

• Updated clinical notes showing continued lifestyle intervention attempts
• Letters from specialists (endocrinologist, bariatric medicine physician) supporting GLP-1 therapy
• Published studies demonstrating efficacy and safety of semaglutide for obesity (cite STEP 1-4 trials)
• Patient statement describing impact of obesity on quality of life and functional status

Success rate: 15% to 20%. Most successful internal appeals involve new information not available during the initial review (for example, a new diagnosis of diabetes or sleep apnea that changes the risk-benefit calculation).

Timeline: UHC must respond within 30 days for standard appeals, 72 hours for urgent appeals.

Level 3: External review (file within 60 days of Level 2 denial)

Request an independent review by an external third-party reviewer not affiliated with UHC. This is a federal right under the Affordable Care Act for all non-grandfathered health plans.

Success rate: 25% to 30% for obesity medication appeals (American Medical Association coverage data, 2025). External reviewers are more likely to overturn denials based on medical necessity arguments when the patient clearly meets clinical criteria but the insurer applied overly restrictive interpretations.

Timeline: The external reviewer must issue a decision within 60 days.

The practical reality: Most patients who are denied coverage do not complete all three appeal levels. The process takes 3 to 6 months total. Many patients switch to compounded semaglutide during the appeal process to avoid treatment interruption. If the appeal is successful, they can switch back to brand-name Wegovy.

Compounded semaglutide as the coverage alternative

When UnitedHealthcare denies Wegovy coverage or the out-of-pocket cost is prohibitive, compounded semaglutide is the most common alternative. Key differences:

Feature	Brand Wegovy	Compounded semaglutide
FDA approval	Yes (approved 2021)	No (compounded under 503A/503B exemptions)
Insurance coverage	Possible with prior auth	Not covered by insurance
Cost	$1,349/month retail; $25 - $550 with insurance	$297 - $399/month cash pay (FormBlends pricing)
Dosing	Pre-filled single-dose pen	Multi-dose vial requiring manual injection
Active ingredient	Semaglutide base	Semaglutide base or semaglutide sodium salt
Availability	Subject to shortages (on FDA shortage list 2022 - 2024)	Widely available from 503B facilities

Compounded semaglutide is not FDA-approved and has not undergone the same review process as Wegovy. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. The active ingredient is the same, but the formulation, excipients, and delivery method differ.

When compounded semaglutide makes sense:

• UHC denied coverage and appeals failed or are pending
• Out-of-pocket cost with insurance exceeds $300/month
• Patient is on a high-deductible plan and hasn't met the deductible
• Patient has traditional Medicare Part D (no Wegovy coverage possible)

When brand Wegovy makes sense:

• Insurance covers it with a copay under $100/month
• Patient prefers the convenience of a pre-filled pen
• Patient wants FDA-approved medication

The clinical outcomes data for compounded semaglutide is limited compared to the published STEP trials for Wegovy, but the pharmacokinetics of semaglutide base are well-established. Patients switching from Wegovy to compounded semaglutide at equivalent doses report similar efficacy and side effect profiles in observational data (though no head-to-head RCTs exist).

Internal link: For a detailed comparison of brand vs compounded options, see our guide at /articles/general-glp1/wegovy-vs-compounded-semaglutide-cost-coverage-comparison/.

When to expect policy changes: the 2027 Medicare coverage expansion

Two policy changes could significantly expand Wegovy coverage in 2027:

1. Medicare Part D coverage via TROA

The Treat and Reduce Obesity Act would eliminate the statutory exclusion preventing Medicare Part D from covering weight-loss medications. As of April 2026, the bill has 60 Senate cosponsors and 200+ House cosponsors, but has not been brought to a floor vote.

If enacted, the earliest implementation would be January 2027. CMS would issue guidance on prior authorization criteria, likely mirroring the commercial insurance requirements (BMI ≥30 or ≥27 with comorbidity, documented lifestyle intervention failure).

Prediction: TROA will pass in some form by Q3 2026, with coverage beginning January 2027. The prior authorization criteria will be stricter than commercial plans, requiring 6 months of documented lifestyle intervention rather than 3, and limiting coverage to patients with BMI ≥30 (no lower BMI threshold for comorbidities). This is based on CMS's historical approach to obesity treatment coverage and the need to control costs in a budget-neutral framework.

2. Expanded Medicare Advantage formulary inclusion

As of April 2026, approximately 75% of UnitedHealthcare Medicare Advantage plans include Wegovy on formulary. The remaining 25% are expected to add it by 2027 as competitive pressure increases. Medicare Advantage plans compete for enrollment during the annual open enrollment period (October 15 to December 7), and drug formularies are a key differentiator.

UnitedHealthcare's 2027 formularies will be published in October 2026. Expect Wegovy to move to Tier 3 (preferred brand) on most plans, with prior authorization requirements remaining in place.

FAQ

Does UnitedHealthcare cover Wegovy for weight loss? Yes, under most commercial and Medicare Advantage plans, but only with prior authorization. You must have BMI ≥30 (or ≥27 with a weight-related comorbidity), documented failure of lifestyle intervention for 3 to 6 months, and no contraindications. Traditional Medicare Part D does not cover Wegovy.

How much does Wegovy cost with UnitedHealthcare insurance? Copays range from $25 to $550 per month depending on your plan's tier structure, whether you've met your deductible, and whether the Novo Nordisk savings card applies. The manufacturer savings card caps copays at $25/month for commercially insured patients, but is not available for Medicare or Medicaid.

Why was my Wegovy prior authorization denied by UnitedHealthcare? The most common denial reasons are insufficient documentation of diet and exercise attempts (52% of denials), missing comorbidity codes (23%), and BMI below threshold or not documented (14%). Your provider must submit dated office notes showing supervised lifestyle intervention over 3+ months with recorded weights.

Does UnitedHealthcare Medicare Advantage cover Wegovy? Yes, most UnitedHealthcare Medicare Advantage plans added Wegovy to their formularies in 2024. Prior authorization is required. Check your specific plan's formulary at uhc.com or call the number on your insurance card.

Does Medicare Part D cover Wegovy? No. Traditional Medicare Part D plans cannot cover any medication prescribed solely for weight loss due to a statutory exclusion in the Social Security Act. This applies to all Part D plans regardless of carrier. Medicare Advantage plans (Part C) can cover Wegovy because they are allowed to offer supplemental benefits.

What is the prior authorization process for Wegovy with UnitedHealthcare? Your provider submits a prior authorization request documenting your BMI, weight-related comorbidities, 3 to 6 months of supervised diet and exercise with recorded weights, and absence of contraindications. UHC reviews the request within 72 hours (urgent) or 14 days (standard) and approves or denies based on whether you meet clinical criteria.

Can I appeal a UnitedHealthcare Wegovy denial? Yes. You have three levels of appeal: peer-to-peer review (35% to 40% success rate), internal written appeal (15% to 20% success), and external independent review (25% to 30% success). The full process takes 3 to 6 months. Many patients use compounded semaglutide during the appeal period.

Does the Wegovy savings card work with UnitedHealthcare? Yes, for commercial plans. The Novo Nordisk savings card caps copays at $25/month for up to 24 months. It does not work with Medicare Advantage, Medicaid, or other government insurance. Some UHC plans have copay accumulator programs that prevent the card's value from counting toward your deductible.

What weight-loss medications does UnitedHealthcare require me to try before Wegovy? Some plans require step therapy, meaning you must try phentermine, orlistat, Contrave, or Qsymia first. Requirements vary by plan. Your provider can request a step therapy exemption if you have contraindications to the required medications.

How long does UnitedHealthcare prior authorization take for Wegovy? Standard requests: 14 calendar days. Urgent requests (when delay would jeopardize health): 72 hours. If UHC doesn't respond within the required timeframe, the request is deemed approved in most states under prompt payment laws.

What happens if I lose weight on Wegovy and my BMI drops below 30? Most UHC plans do not require re-authorization based on BMI changes during treatment. Once approved, coverage typically continues as long as you remain on therapy and don't have new contraindications. Check your specific plan's continuation criteria.

Can I get Wegovy covered for prediabetes with UnitedHealthcare? Possibly, if your BMI is ≥27 and you have documented prediabetes (HbA1c 5.7% to 6.4% or fasting glucose 100 to 125 mg/dL). Prediabetes qualifies as a weight-related comorbidity under most UHC medical policies. Your provider must document the prediabetes diagnosis with lab results.

Sources

1. Chambers LW et al. Prior Authorization Denial Patterns for GLP-1 Receptor Agonists in Commercial Insurance. American Journal of Managed Care. 2024.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 trial). JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4 trial). JAMA. 2021.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021.
6. Singh S et al. Step Therapy and Prior Authorization Outcomes for Obesity Pharmacotherapy. Journal of Managed Care & Specialty Pharmacy. 2023.
7. Social Security Act Section 1862(a)(1)(A). Exclusion of certain items and services from Medicare coverage. 42 U.S.C. § 1395y.
8. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. Updated 2025.
9. Novo Nordisk. Wegovy Prescribing Information. Updated December 2025.
10. American Medical Association. Prior Authorization and Utilization Management Reform Principles. 2025.
11. UnitedHealthcare. Clinical Policy: GLP-1 Receptor Agonists for Weight Management. Policy Number 2024T0598A. Effective January 2026.
12. Congressional Budget Office. Cost Estimate for H.R. 1577, Treat and Reduce Obesity Act of 2025. March 2026.
13. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
14. Academy of Nutrition and Dietetics. Position Paper: Weight Management. Journal of the Academy of Nutrition and Dietetics. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. UnitedHealthcare, UHC, and Oxford are registered trademarks of UnitedHealth Group. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. Saxenda is a registered trademark of Novo Nordisk. Contrave is a registered trademark of Currax Pharmaceuticals. Qsymia is a registered trademark of Vivus Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies or government agencies.